Stcube announces interim results from Phase 2 trial in non-small cell lung cancer… 73% patient enrollment
Predicted impact: Medium
Phase 2 interim results for lung cancer drug; material for a ₩471B company.
Stcube에스티큐브
052020 · KOSDAQ · ₩052020 · 에스티큐브
₩6,830▼ ₩100 (1.44%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −18.40%
- Market cap
- ₩464B
- Enterprise value
- ₩406B
- P/E
- —
- P/B
- 7.7×
- Dividend yield
- 0.0%
- ROE
- −39.9%
- Net margin
- −338.7%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−69.6% from the high
₩6,010Today: ₩6,790 – ₩7,020₩22,500
Returns
- 1W−6.3%
- 1M−14.7%
- 3M−2.4%
- 6M−66.7%
- YTD−16.7%
- 1Y−18.4%
- Volume today
- 140,033
- 1.0× the 20-day average
- Traded today
- ₩964M
- Listed shares
- 67,983,291
- EPS (12 months)
- −₩354
- Earnings yield −5.2%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 45 of 100 (50 is a normal day for this stock).
- MomentumWeak-11.3% over the last month; the price is below its 20-day average.
- News impactSome1 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Sep 4: buy ₩765M at the close (64.7% of 20-day average trading value)
On its 26 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 14.1% of trading value and pointed the same way 5 of 26 times.
- 2× KODEX KOSDAQ150 Leverage ₩685M
- -1× KODEX KOSDAQ150 Futures Inverse ₩42M
- 2× TIGER KOSDAQ150 Leverage ₩27M
- 2× RISE KOSDAQ150 Futures Leverage ₩7.4M
- -1× TIGER KOSDAQ150 Futures Inverse ₩1.2M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
Stcube stock overview
Stcube (에스티큐브, KRX: 052020) is listed on KOSDAQ, in the Retail & Trade sector. Sci-Tech Cube (STCube) is a Korean company operating a biotech segment and a distribution segment. Its shares closed at ₩6,830 on Oct 27, 2026, down 1.44% on the day, giving it a market value of ₩464B.
Key facts
- Market cap
- ₩464B
- Sector
- Retail & Trade
- Latest price change
- −1.44%
- As of
- Oct 27, 2026
- Main business
- Sci-Tech Cube (STCube) is a Korean company operating a biotech segment and a distribution segment.
Quick answers about Stcube
- What does Stcube do?
- Sci-Tech Cube (STCube) is a Korean company operating a biotech segment and a distribution segment. S. subsidiary STCube Pharmaceuticals, develops cancer immunotherapy and immune checkpoint inhibitor drugs, including the novel candidate Nelmastobart, which targets BTN1A1.
- What is the market cap of Stcube?
- The market capitalisation of Stcube was ₩464B at the close on Oct 27, 2026.
- Who are the largest shareholders of Stcube?
- According to the latest official filings, the largest reported holders are STQ&Company (8.02%, as of Dec 3, 2024); Bio Medical Holdings (1.66%, as of Jun 30, 2025); YOO STEPHEN (0.85%, as of Dec 3, 2024).
- When is the next earnings report from Stcube?
- Korean companies rarely announce results dates in advance. Based on when Stcube filed the same report in past years, its next 3q results is expected between Nov 1, 2026 and Nov 14, 2026.
- Does the National Pension Service own Stcube?
- Yes. The National Pension Service held 0.34% of Stcube shares as of Dec 31, 2023.
Company profile
Sci-Tech Cube (STCube) is a Korean company operating a biotech segment and a distribution segment. Its biotech unit, working with its U.S. subsidiary STCube Pharmaceuticals, develops cancer immunotherapy and immune checkpoint inhibitor drugs, including the novel candidate Nelmastobart, which targets BTN1A1. Its distribution unit sells cosmetics under its own Scenearth brand through online channels, Olive Young, and duty-free shops, exports to Japan and Taiwan, and imports and distributes industrial lens modules from China, mainly within Korea.
Written by AI from the company's latest annual report.
- Korean name
- 에스티큐브
- Sector
- Retail & Trade
- Themes
- —
- CEO
- 정현진
- Founded
- Aug 1989
- Listed
- Jul 2001
- Listed shares
- 67,983,291
- Fiscal year ends
- Month 12
- Website
- www.stcube.com
Similar companies
- Samsung C&T028260 · ₩49T₩301,000+3.08%
- POSCO International047050 · ₩8.8T₩49,850+0.61%
- ISC095340 · ₩3.2T₩151,300+7.61%
- Youngone111770 · ₩3T₩68,100+1.04%
- Dong SUH Companies026960 · ₩2.7T₩27,500+0.73%
- Shinsegae004170 · ₩2.3T₩245,0000.00%
- SK Gas018670 · ₩2.3T₩249,000−0.80%
- Lotte Shopping023530 · ₩2.3T₩81,300−0.12%
Recent news
STcube unveils three development axes for nelmastobart at ESMO, announces combination expansion strategy
Predicted impact: Low· Actual: +9.2% vs sector, volume 0.8× normal (5 trading days)
ESMO data presentation was already announced in the last 14 days.
S-Cube Presents Three Studies on Nemvastobart at ESMO, Outlines Combination Therapy Expansion Strategy
Predicted impact: Low· Actual: +9.2% vs sector, volume 0.8× normal (5 trading days)
Conference presentations of drug study data; no revenue size disclosed, routine clinical news.
Recent filings
See all- Added attachment: Half-year report (Jun 2026)Aug 14, 2026
- Quarterly report (Mar 2026)May 15, 2026
- Annual general meeting resultsMar 26, 2026
- Audit report submittedMar 18, 2026
- Annual report (Dec 2025)Mar 18, 2026
Titles in Korean until English translations are added.
Also known as: Stcube / 에스티큐브 / 052020 / KRX:052020
Source: KRX statistical information